BioSpace News Archive

Rising prevalence of various infectious and chronic diseases along with technological advancements in NGS platforms are key factors fueling market growth.

Targeted Oncology is excited to announce three additions to its Strategic Alliance Partnership (SAP) Program.

VastBiome is announcing sponsorship of an observational clinical study designed to collect data to understand molecular associations between immune checkpoint inhibitor (ICI) therapy and the gut microbiome (the collection of bacteria and other bugs living in the gastrointestinal tract).

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.

Newly published in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

U.S. FDA Approves Pfizer’s CIBINQO ® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis.

Nabriva Therapeutics plc announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders on January 14, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021.

PacBio announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on January 10, 2022.

In its recent report, Transparency Market Research gives intricate details about the global behavioral health market.